4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) Stock Competitors & Peer Comparison

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while VRTX trades at $508.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas VRTX's P/E ratio is 26.70. In terms of profitability, FDMT's ROE is -0.41%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, FDMT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check VRTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while REGN trades at $784.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas REGN's P/E ratio is 17.20. In terms of profitability, FDMT's ROE is -0.41%, compared to REGN's ROE of +0.14%. Regarding short-term risk, FDMT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check REGN's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas VRNA's P/E ratio is -102.80. In terms of profitability, FDMT's ROE is -0.41%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, FDMT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check VRNA's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ARGX trades at $990.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ARGX's P/E ratio is 89.38. In terms of profitability, FDMT's ROE is -0.41%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, FDMT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ARGX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MRNA trades at $154.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MRNA's P/E ratio is -18.90. In terms of profitability, FDMT's ROE is -0.41%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, FDMT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check MRNA's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas SGEN's P/E ratio is -57.19. In terms of profitability, FDMT's ROE is -0.41%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, FDMT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check SGEN's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RVMD trades at $190.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RVMD's P/E ratio is -21.64. In terms of profitability, FDMT's ROE is -0.41%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, FDMT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RVMD's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RVMDW trades at $9.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, FDMT's ROE is -0.41%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, FDMT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check RVMDW's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ONC trades at $350.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ONC's P/E ratio is 61.77. In terms of profitability, FDMT's ROE is -0.41%, compared to ONC's ROE of +0.14%. Regarding short-term risk, FDMT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ONC's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ALNY trades at $239.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ALNY's P/E ratio is 44.24. In terms of profitability, FDMT's ROE is -0.41%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, FDMT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ALNY's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ROIV trades at $39.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ROIV's P/E ratio is -37.84. In terms of profitability, FDMT's ROE is -0.41%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, FDMT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ROIV's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, INSM has a market cap of 26B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while INSM trades at $120.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas INSM's P/E ratio is -29.20. In terms of profitability, FDMT's ROE is -0.41%, compared to INSM's ROE of -1.11%. Regarding short-term risk, FDMT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check INSM's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while INCY trades at $125.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas INCY's P/E ratio is 16.84. In terms of profitability, FDMT's ROE is -0.41%, compared to INCY's ROE of +0.30%. Regarding short-term risk, FDMT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check INCY's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while BNTX trades at $96.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas BNTX's P/E ratio is -12.46. In terms of profitability, FDMT's ROE is -0.41%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, FDMT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check BNTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while GMAB trades at $34.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas GMAB's P/E ratio is 26.18. In terms of profitability, FDMT's ROE is -0.41%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, FDMT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check GMAB's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while UTHR trades at $494.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas UTHR's P/E ratio is 17.70. In terms of profitability, FDMT's ROE is -0.41%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, FDMT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check UTHR's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas BGNE's P/E ratio is -22.55. In terms of profitability, FDMT's ROE is -0.41%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, FDMT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check BGNE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, FDMT's ROE is -0.41%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, FDMT is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check DNA-WT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while JAZZ trades at $240.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, FDMT's ROE is -0.41%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, FDMT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check JAZZ's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while NBIX trades at $146.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas NBIX's P/E ratio is 21.13. In terms of profitability, FDMT's ROE is -0.41%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, FDMT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check NBIX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ASND trades at $236.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ASND's P/E ratio is -97.82. In terms of profitability, FDMT's ROE is -0.41%, compared to ASND's ROE of +1.90%. Regarding short-term risk, FDMT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ASND's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while EXEL trades at $58.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas EXEL's P/E ratio is 16.67. In terms of profitability, FDMT's ROE is -0.41%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, FDMT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check EXEL's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while SMMT trades at $17.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas SMMT's P/E ratio is -15.94. In terms of profitability, FDMT's ROE is -0.41%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, FDMT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check SMMT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while HALO trades at $112.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas HALO's P/E ratio is 20.98. In terms of profitability, FDMT's ROE is -0.41%, compared to HALO's ROE of +1.81%. Regarding short-term risk, FDMT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check HALO's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while BBIO trades at $66.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas BBIO's P/E ratio is -17.81. In terms of profitability, FDMT's ROE is -0.41%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, FDMT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check BBIO's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas KRTX's P/E ratio is -28.09. In terms of profitability, FDMT's ROE is -0.41%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, FDMT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check KRTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while BMRN trades at $63.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas BMRN's P/E ratio is 30.74. In terms of profitability, FDMT's ROE is -0.41%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, FDMT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check BMRN's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MDGL trades at $531.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MDGL's P/E ratio is -41.52. In terms of profitability, FDMT's ROE is -0.41%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, FDMT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check MDGL's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TECH trades at $72.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TECH's P/E ratio is 37.30. In terms of profitability, FDMT's ROE is -0.41%, compared to TECH's ROE of +0.09%. Regarding short-term risk, FDMT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check TECH's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RNAM's P/E ratio is -17.39. In terms of profitability, FDMT's ROE is -0.41%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, FDMT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RNAM's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while AXSM trades at $207.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas AXSM's P/E ratio is -54.25. In terms of profitability, FDMT's ROE is -0.41%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, FDMT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check AXSM's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TWST trades at $166.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TWST's P/E ratio is -75.22. In terms of profitability, FDMT's ROE is -0.41%, compared to TWST's ROE of -0.30%. Regarding short-term risk, FDMT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check TWST's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while KRYS trades at $336.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas KRYS's P/E ratio is 42.19. In terms of profitability, FDMT's ROE is -0.41%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, FDMT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check KRYS's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TXG trades at $76.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TXG's P/E ratio is -129.83. In terms of profitability, FDMT's ROE is -0.41%, compared to TXG's ROE of -0.09%. Regarding short-term risk, FDMT is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check TXG's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while KYMR trades at $117.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas KYMR's P/E ratio is -36.80. In terms of profitability, FDMT's ROE is -0.41%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, FDMT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check KYMR's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RXDX's P/E ratio is -56.47. In terms of profitability, FDMT's ROE is -0.41%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, FDMT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RXDX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ARWR trades at $66.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ARWR's P/E ratio is -29.55. In terms of profitability, FDMT's ROE is -0.41%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, FDMT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ARWR's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while PTGX trades at $143.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas PTGX's P/E ratio is 138.83. In terms of profitability, FDMT's ROE is -0.41%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, FDMT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check PTGX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas NUVL's P/E ratio is -21.79. In terms of profitability, FDMT's ROE is -0.41%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, FDMT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check NUVL's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CRNX's P/E ratio is -16.86. In terms of profitability, FDMT's ROE is -0.41%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, FDMT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CRNX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while IBRX trades at $8.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas IBRX's P/E ratio is -8.74. In terms of profitability, FDMT's ROE is -0.41%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, FDMT is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check IBRX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas IMGN's P/E ratio is -111.55. In terms of profitability, FDMT's ROE is -0.41%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, FDMT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check IMGN's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TGTX trades at $56.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TGTX's P/E ratio is 20.61. In terms of profitability, FDMT's ROE is -0.41%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, FDMT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check TGTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CYTK trades at $68.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CYTK's P/E ratio is -9.53. In terms of profitability, FDMT's ROE is -0.41%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, FDMT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CYTK's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CAI trades at $29.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CAI's P/E ratio is 84.24. In terms of profitability, FDMT's ROE is -0.41%, compared to CAI's ROE of +0.19%. Regarding short-term risk, FDMT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CAI's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while PCVX trades at $58.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas PCVX's P/E ratio is -7.62. In terms of profitability, FDMT's ROE is -0.41%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, FDMT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check PCVX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas BPMC's P/E ratio is -51.58. In terms of profitability, FDMT's ROE is -0.41%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, FDMT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check BPMC's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas APGE's P/E ratio is -31.19. In terms of profitability, FDMT's ROE is -0.41%, compared to APGE's ROE of -0.30%. Regarding short-term risk, FDMT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check APGE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while PRAX trades at $298.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas PRAX's P/E ratio is -23.12. In terms of profitability, FDMT's ROE is -0.41%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, FDMT is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check PRAX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CERE's P/E ratio is -16.47. In terms of profitability, FDMT's ROE is -0.41%, compared to CERE's ROE of -0.72%. Regarding short-term risk, FDMT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CERE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while SYRE trades at $90.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas SYRE's P/E ratio is -46.28. In terms of profitability, FDMT's ROE is -0.41%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, FDMT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check SYRE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ABVX trades at $105.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ABVX's P/E ratio is -55.06. In terms of profitability, FDMT's ROE is -0.41%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, FDMT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ABVX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while IMVT trades at $36.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas IMVT's P/E ratio is -13.10. In terms of profitability, FDMT's ROE is -0.41%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, FDMT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check IMVT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MTSR's P/E ratio is -23.58. In terms of profitability, FDMT's ROE is -0.41%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, FDMT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check MTSR's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while IONS trades at $44.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas IONS's P/E ratio is -25.84. In terms of profitability, FDMT's ROE is -0.41%, compared to IONS's ROE of -1.11%. Regarding short-term risk, FDMT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check IONS's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while BLTE trades at $170.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas BLTE's P/E ratio is -91.42. In terms of profitability, FDMT's ROE is -0.41%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, FDMT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check BLTE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MRUS's P/E ratio is -17.05. In terms of profitability, FDMT's ROE is -0.41%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, FDMT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check MRUS's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ACLX's P/E ratio is -28.27. In terms of profitability, FDMT's ROE is -0.41%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, FDMT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ACLX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RYTM trades at $97.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RYTM's P/E ratio is -31.42. In terms of profitability, FDMT's ROE is -0.41%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, FDMT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RYTM's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CGON trades at $74.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CGON's P/E ratio is -27.74. In terms of profitability, FDMT's ROE is -0.41%, compared to CGON's ROE of -0.25%. Regarding short-term risk, FDMT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CGON's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RETA's P/E ratio is -66.29. In terms of profitability, FDMT's ROE is -0.41%, compared to RETA's ROE of +0.47%. Regarding short-term risk, FDMT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RETA's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CNTA's P/E ratio is -22.63. In terms of profitability, FDMT's ROE is -0.41%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, FDMT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CNTA's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TVTX trades at $62.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TVTX's P/E ratio is -139.47. In terms of profitability, FDMT's ROE is -0.41%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, FDMT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check TVTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ORKA trades at $94.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ORKA's P/E ratio is -48.95. In terms of profitability, FDMT's ROE is -0.41%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, FDMT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ORKA's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while LGND trades at $283.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas LGND's P/E ratio is 31.12. In terms of profitability, FDMT's ROE is -0.41%, compared to LGND's ROE of +0.20%. Regarding short-term risk, FDMT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check LGND's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CDTX's P/E ratio is -19.77. In terms of profitability, FDMT's ROE is -0.41%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, FDMT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CDTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MIRM trades at $91.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MIRM's P/E ratio is -6.31. In terms of profitability, FDMT's ROE is -0.41%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, FDMT is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check MIRM's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while SRRK trades at $46.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas SRRK's P/E ratio is -13.52. In terms of profitability, FDMT's ROE is -0.41%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, FDMT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check SRRK's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, FDMT's ROE is -0.41%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, FDMT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ABCM's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ISEE's P/E ratio is -22.44. In terms of profitability, FDMT's ROE is -0.41%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, FDMT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ISEE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while PTCT trades at $65.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas PTCT's P/E ratio is -28.06. In terms of profitability, FDMT's ROE is -0.41%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, FDMT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check PTCT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CRSP trades at $56.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CRSP's P/E ratio is -11.88. In terms of profitability, FDMT's ROE is -0.41%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, FDMT is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check CRSP's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while DNTH trades at $96.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas DNTH's P/E ratio is -23.33. In terms of profitability, FDMT's ROE is -0.41%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, FDMT is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check DNTH's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while COGT trades at $31.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas COGT's P/E ratio is -14.93. In terms of profitability, FDMT's ROE is -0.41%, compared to COGT's ROE of -0.73%. Regarding short-term risk, FDMT is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check COGT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas APLS's P/E ratio is 38.35. In terms of profitability, FDMT's ROE is -0.41%, compared to APLS's ROE of +0.40%. Regarding short-term risk, FDMT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check APLS's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while DFTX trades at $38.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas DFTX's P/E ratio is N/A. In terms of profitability, FDMT's ROE is -0.41%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, FDMT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check DFTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ERAS trades at $14.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ERAS's P/E ratio is -15.88. In terms of profitability, FDMT's ROE is -0.41%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, FDMT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check ERAS's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while EWTX trades at $45.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas EWTX's P/E ratio is -24.50. In terms of profitability, FDMT's ROE is -0.41%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, FDMT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check EWTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while PBLS trades at $41.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas PBLS's P/E ratio is -47.42. In terms of profitability, FDMT's ROE is -0.41%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, FDMT is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check PBLS's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TERN's P/E ratio is -51.41. In terms of profitability, FDMT's ROE is -0.41%, compared to TERN's ROE of -0.20%. Regarding short-term risk, FDMT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check TERN's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ACAD trades at $27.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ACAD's P/E ratio is 12.29. In terms of profitability, FDMT's ROE is -0.41%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, FDMT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ACAD's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while IOVA trades at $10.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas IOVA's P/E ratio is -14.04. In terms of profitability, FDMT's ROE is -0.41%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, FDMT is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check IOVA's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ADPT trades at $28.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ADPT's P/E ratio is -69.63. In terms of profitability, FDMT's ROE is -0.41%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, FDMT is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ADPT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas FOLD's P/E ratio is -161.00. In terms of profitability, FDMT's ROE is -0.41%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, FDMT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check FOLD's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas AKRO's P/E ratio is -14.57. In terms of profitability, FDMT's ROE is -0.41%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, FDMT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check AKRO's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ALPN's P/E ratio is -101.52. In terms of profitability, FDMT's ROE is -0.41%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, FDMT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ALPN's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MANE trades at $106.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MANE's P/E ratio is -33.96. In terms of profitability, FDMT's ROE is -0.41%, compared to MANE's ROE of -0.38%. Regarding short-term risk, FDMT is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check MANE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while TLX trades at $12.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas TLX's P/E ratio is 131.42. In terms of profitability, FDMT's ROE is -0.41%, compared to TLX's ROE of +0.07%. Regarding short-term risk, FDMT is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check TLX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas OPT's P/E ratio is -1.52. In terms of profitability, FDMT's ROE is -0.41%, compared to OPT's ROE of +1.18%. Regarding short-term risk, FDMT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check OPT's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas PRTC's P/E ratio is -3.78. In terms of profitability, FDMT's ROE is -0.41%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, FDMT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check PRTC's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RLAY trades at $18.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RLAY's P/E ratio is -12.00. In terms of profitability, FDMT's ROE is -0.41%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, FDMT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RLAY's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas MRTX's P/E ratio is -4.82. In terms of profitability, FDMT's ROE is -0.41%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, FDMT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check MRTX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CELC trades at $80.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CELC's P/E ratio is -18.75. In terms of profitability, FDMT's ROE is -0.41%, compared to CELC's ROE of -3.51%. Regarding short-term risk, FDMT is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check CELC's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while ABCL trades at $12.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas ABCL's P/E ratio is -23.39. In terms of profitability, FDMT's ROE is -0.41%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, FDMT is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check ABCL's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CPRX's P/E ratio is 12.30. In terms of profitability, FDMT's ROE is -0.41%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, FDMT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CPRX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while XENE trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas XENE's P/E ratio is -8.46. In terms of profitability, FDMT's ROE is -0.41%, compared to XENE's ROE of -0.44%. Regarding short-term risk, FDMT is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for FDMT.Check XENE's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while AMLX trades at $32.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas AMLX's P/E ratio is -22.63. In terms of profitability, FDMT's ROE is -0.41%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, FDMT is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check AMLX's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas RYZB's P/E ratio is -57.86. In terms of profitability, FDMT's ROE is -0.41%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, FDMT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check RYZB's competition here

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FDMT stands at 795.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, FDMT is priced at $15.22 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FDMT currently has a P/E ratio of -5.92, whereas CBAY's P/E ratio is -32.81. In terms of profitability, FDMT's ROE is -0.41%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, FDMT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for FDMT.Check CBAY's competition here